CD274 and triple-negative breast carcinoma: In fact, the lack of immunotherapy benefit observed in our small PD-L1-positive cohort may be a false negative, based on larger trials in metastatic triple-negative breast cancer showing that immunotherapy added to chemotherapy improves clinical outcomes in patients with PD-L1-positive disease8,40.